dactinomycin has been researched along with sincalide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carstens, OC; Fölsch, UR; Günther, R; Schmidt, WE | 1 |
| Cao, Y; Hu, C; Peng, L | 1 |
1 review(s) available for dactinomycin and sincalide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for dactinomycin and sincalide
| Article | Year |
|---|---|
Transient agonist-induced regulation of the cholecystokinin-A and cholecystokinin-B receptor mRNA levels in rat pancreatic acinar AR42J cells.
Topics: Animals; Benzodiazepinones; Bucladesine; Cell Line; Colforsin; Dactinomycin; Down-Regulation; Gastrins; Pancreas; Phenylurea Compounds; Rats; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; RNA, Messenger; Sincalide; Tetradecanoylphorbol Acetate; Up-Regulation | 2003 |
Identification of exosomal circRNA CD226 as a potent driver of nonsmall cell lung cancer through miR-1224-3p/high mobility group AT-hook 2 axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dactinomycin; Humans; Lung Neoplasms; MicroRNAs; Ribonucleases; RNA, Circular; Sincalide | 2022 |